Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences
Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in key December investor and scientific conferences. The company will present at the Piper Sandler 36th Annual Healthcare Conference with a fireside chat on December 3rd, 2024, featuring CEO Pravin U. Dugel. Additionally, the company will have a significant presence at FLORetina ICOOR 2024 in Florence, Italy, with multiple presentations scheduled between December 5-7, 2024.
The presentations will focus on their OTX-TKI treatment, including 48-week results from the HELIOS Phase I Trial for non-proliferative diabetic retinopathy, and discussions on TKIs in retinal disease management. Multiple sessions will feature presentations by leading medical experts including Dr. Dilsher S. Dhoot and Dr. Diana V. Do.
Ocular Therapeutix (NASDAQ: OCUL) ha annunciato la sua partecipazione a importanti conferenze per investitori e scientifiche a dicembre. L'azienda presenterà al Piper Sandler 36th Annual Healthcare Conference con un'intervista a fuoco il 3 dicembre 2024, con il CEO Pravin U. Dugel. Inoltre, l'azienda avrà una presenza significativa all'FLORetina ICOOR 2024 a Firenze, Italia, con numerose presentazioni in programma dal 5 al 7 dicembre 2024.
Le presentazioni si concentreranno sul trattamento OTX-TKI, inclusi i risultati a 48 settimane della Fase I dello studio HELIOS per la retinopatia diabetica non proliferativa, e discuteranno dei TKI nella gestione delle malattie retiniche. Diverse sessioni presenteranno relatori di spicco, tra cui il Dr. Dilsher S. Dhoot e la Dr.ssa Diana V. Do.
Ocular Therapeutix (NASDAQ: OCUL) ha anunciado su participación en importantes conferencias de inversión y científicas en diciembre. La empresa presentará en la Piper Sandler 36th Annual Healthcare Conference con un chat al calor de la chimenea el 3 de diciembre de 2024, con el CEO Pravin U. Dugel. Además, la empresa tendrá una presencia significativa en el FLORetina ICOOR 2024 en Florencia, Italia, con múltiples presentaciones programadas entre el 5 y el 7 de diciembre de 2024.
Las presentaciones se centrarán en su tratamiento OTX-TKI, incluidos los resultados a 48 semanas del ensayo HELIOS de Fase I para la retinopatía diabética no proliferativa, y discutirán sobre los TKI en la gestión de enfermedades de la retina. Varias sesiones contarán con presentaciones de destacados expertos médicos, incluidos el Dr. Dilsher S. Dhoot y la Dra. Diana V. Do.
Ocular Therapeutix (NASDAQ: OCUL)는 12월에 열리는 주요 투자자 및 과학 회의에 참가한다고 발표했습니다. 이 회사는 2024년 12월 3일, CEO Pravin U. Dugel과 함께하는 화상 대담을 통해 Piper Sandler 36th Annual Healthcare Conference에서 발표할 예정입니다. 또한, 2024년 12월 5일부터 7일 사이에 이탈리아 피렌체에서 열리는 FLORetina ICOOR 2024에서도 중요한 발표를 진행합니다.
발표 내용은 비증식성 당뇨병성 망막병증에 대한 HELIOS 1상 시험의 48주 결과를 포함한 OTX-TKI 치료에 초점을 맞추며, 망막 질환 관리에서의 TKI에 대한 논의도 포함됩니다. 여러 세션에서는 Dr. Dilsher S. Dhoot 및 Dr. Diana V. Do와 같은 저명한 의료 전문가들의 발표가 있을 예정입니다.
Ocular Therapeutix (NASDAQ: OCUL) a annoncé sa participation à des conférences clés pour investisseurs et scientifiques en décembre. L'entreprise présentera lors de la Piper Sandler 36th Annual Healthcare Conference avec une discussion au coin du feu le 3 décembre 2024, mettant en vedette le PDG Pravin U. Dugel. De plus, l'entreprise aura une présence significative au FLORetina ICOOR 2024 à Florence, en Italie, avec plusieurs présentations prévues entre le 5 et le 7 décembre 2024.
Les présentations mettront l'accent sur leur traitement OTX-TKI, y compris les résultats à 48 semaines de l'essai HELIOS de phase I pour la rétinopathie diabétique non proliférative, ainsi que des discussions sur les TKI dans la gestion des maladies rétiniennes. Plusieurs sessions présenteront des intervenants médicaux de renom, notamment le Dr Dilsher S. Dhoot et la Dr Diana V. Do.
Ocular Therapeutix (NASDAQ: OCUL) hat seine Teilnahme an wichtigen Investoren- und Wissenschaftskonferenzen im Dezember bekannt gegeben. Das Unternehmen wird am 3. Dezember 2024 beim Piper Sandler 36th Annual Healthcare Conference mit einem Gespräch am Kamin, das CEO Pravin U. Dugel leitet, präsentieren. Darüber hinaus wird das Unternehmen eine bedeutende Präsenz auf dem FLORetina ICOOR 2024 in Florenz, Italien, mit mehreren Präsentationen zwischen dem 5. und 7. Dezember 2024 haben.
Die Präsentationen konzentrieren sich auf die OTX-TKI-Behandlung, einschließlich der 48-Wochen-Ergebnisse der HELIOS Phase-I-Studie zur nicht-proliferativen diabetischen Retinopathie und diskutieren über TKIs im Management von Netzhauterkrankungen. In mehreren Sitzungen werden führende Mediziner wie Dr. Dilsher S. Dhoot und Dr. Diana V. Do präsentieren.
- None.
- None.
BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in several investor and scientific conferences being held in December.
Piper Sandler 36th Annual Healthcare Conference
Fireside Chat Date: Tuesday, December 3rd, 2024
Fireside Chat Time: 1:30 PM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: New York City, NY
The live fireside chat can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.
FLORetina ICOOR 2024
Florence, Italy
- 48-week Results from the HELIOS Phase I Trial Evaluating Intravitreal OTX-TKI for Non-proliferative Diabetic Retinopathy
Session: Highlighted New Drugs DME
Presentation Date/Time: Thursday, December 5, 2024, 1:33 – 1:36PM CET
Presenter: Dilsher S. Dhoot, MD
- OTX-TKI – The Evolution of Optimized AXPAXLI (AUS >> US >> SOL-1)
Session: Retina Futura 1: Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical Updates
Presentation Date/Time Friday, December 6, 2024, 11:29 – 11:33AM CET
Presenter: Diana V. Do, MD
- HELIOS: Phase 1 SAFETY Study of AXPAXLI in NPDR
Session: Retina Futura 2: Diabetic Retinal Diseases and Retinal Detachment
Presentation Date/Time: Friday, December 6, 2024, 2:12 – 2:16PM CET
Presenter: Dilsher S. Dhoot, MD
- TKIs in the Future of Retinal Disease Management
Session: Afternoon Symposium
Session Date/Time: Saturday, December 7, 2024, 3:30 – 4:30 PM CET
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When is Ocular Therapeutix (OCUL) presenting at the Piper Sandler Healthcare Conference?
What clinical trial results will OCUL present at FLORetina ICOOR 2024?
How many presentations will Ocular Therapeutix make at FLORetina ICOOR 2024?
